Document is current
Any future updates will be listed below
-
Authors
Berron, David http://orcid.org/0000-0003-1558-1883
Glanz, Wenzel
Clark, Lindsay
Basche, Kristin
Grande, Xenia http://orcid.org/0000-0002-2486-3201
Güsten, Jeremie
Billette, Ornella V.
Hempen, Ina
Naveed, Muhammad Hashim
Diersch, Nadine
Butryn, Michaela
Spottke, Annika
Buerger, Katharina
Perneczky, Robert
Schneider, Anja
Teipel, Stefan
Wiltfang, Jens
Johnson, Sterling
Wagner, Michael http://orcid.org/0000-0003-2589-6440
Jessen, Frank
Düzel, Emrah
- License Information
-
More Information
Article History
Received: 15 June 2023
Accepted: 3 January 2024
First Online: 26 March 2024
Competing interests
: D.B. reports personal fees from neotiv GmbH during the conduct of the study. O.V.B., I.H., M.H.N., and N.D. are full employees of neotiv GmbH and report personal fees from neotiv GmbH during the conduct of the study. S.T. reports Advisory Board Membership for Biogen, Roche, and Grifols. J.W. reports personal fees from Abbott, Biogen, Boehringer-Ingelheim, Eli Lilly, MSD SHARP Dohme, Roche, Janssen Cilag, Immunogenetics, Roboscreen, and Pfizer during the conduct of the study. S.C.J. has, in the past 2 years, served on advisory boards to Roche Diagnostics, Prothena, AlzPath, Merck and Eisai. His institution has received research funding from Cerveau Technologies. E.D. reports personal fees from neotiv GmbH during the conduct of the study and personal fees from Biogen, Roche, Lilly, Eisai, and UCL Consultancy, as well as non-financial support from Rox Health outside the submitted work. D.B. and E.D. are co-founders of neotiv GmbH and own company shares. W.G., X.G., J.G., M.H.N., M.B., A. Sp, A.S., K.B., M.W., R.P., and F.J., L.C., K.B. have no competing interest to disclose.
